Evidence map›Paper›PMID 33340276›Full record

ArticleCancer medicine2021

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.

Jessica K Altman, Alexander E Perl, Jason E Hill, Matt Rosales, Erkut Bahceci, Mark J Levis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Venetoclax Plus Gilteritinib forJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  5. Article
  6. Cancers · 2022
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jessica K AltmanRobert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Alexander E PerlAbramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Jason E HillAstellas Pharma US, Inc., Northbrook, IL, USA.
Matt RosalesAstellas Pharma US, Inc., Northbrook, IL, USA.
Erkut BahceciAstellas Pharma US, Inc., Northbrook, IL, USA.
Mark J LevisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Astellas Pharma (United States) · USJohns Hopkins University · USNorthwestern University · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3-mutated (FLT3

Indexed as

MutationAdultAgedAged, 80 and overAniline CompoundsDrug Resistance, NeoplasmFemalefms-Like Tyrosine Kinase 3Follow-Up StudiesHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPrognosisProtein Kinase InhibitorsPyrazinesAniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibProtein Kinase InhibitorsPyrazinesFLT3 inhibitorFms-like tyrosine kinase 3internal tandem duplicationmorphologic remission

Identifiers

PMID33340276
PMCPMC7897940
OpenAlexW3117153437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.